Zoetis Inc. (NYSE:ZTS) Stock Holdings Cut by Alta Capital Management LLC

Alta Capital Management LLC lessened its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 169,791 shares of the company's stock after selling 4,976 shares during the quarter. Zoetis makes up about 1.6% of Alta Capital Management LLC's holdings, making the stock its 24th largest position. Alta Capital Management LLC's holdings in Zoetis were worth $27,664,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp increased its stake in Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company's stock valued at $3,864,488,000 after purchasing an additional 95,856 shares during the last quarter. Geode Capital Management LLC grew its holdings in Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock valued at $2,030,813,000 after buying an additional 185,364 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Zoetis by 8.5% during the 4th quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company's stock valued at $906,202,000 after acquiring an additional 433,429 shares during the last quarter. Mizuho Securities USA LLC lifted its holdings in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Zoetis by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock worth $761,221,000 after acquiring an additional 194,542 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Remove Ads

Zoetis Stock Up 1.8 %

NYSE:ZTS traded up $3.09 during mid-day trading on Friday, reaching $170.34. The stock had a trading volume of 3,296,788 shares, compared to its average volume of 3,274,650. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market capitalization of $76.28 billion, a price-to-earnings ratio of 31.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The stock's 50 day simple moving average is $166.61 and its two-hundred day simple moving average is $176.92.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Monday, April 21st. Zoetis's payout ratio is 36.56%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ZTS shares. UBS Group initiated coverage on shares of Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price target for the company. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 target price on the stock. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Finally, Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.